Abstract

Safeguards against excess DNA replication are often dysregulated in cancer, and driving cancer cells towards over-replication is a promising therapeutic strategy. We determined DNA synthesis patterns in cancer cells undergoing partial genome re-replication due to perturbed regulatory interactions (re-replicating cells). These cells exhibited slow replication, increased frequency of replication initiation events, and a skewed initiation pattern that preferentially reactivated early-replicating origins. Unlike in cells exposed to replication stress, which activated a novel group of hitherto unutilized (dormant) replication origins, the preferred re-replicating origins arose from the same pool of potential origins as those activated during normal growth. Mechanistically, the skewed initiation pattern reflected a disproportionate distribution of pre-replication complexes on distinct regions of licensed chromatin prior to replication. This distinct pattern suggests that circumventing the strong inhibitory interactions that normally prevent excess DNA synthesis can occur via at least two pathways, each activating a distinct set of replication origins.

DNA replication processes are often dysregulated in cancer. Here the authors analyse DNA synthesis patterns in cancer cells undergoing partial genome re-replication to reveal that re-replication exhibits aberrant replication fork dynamics and a skewed distribution of replication initiation that over-duplicates early-replicating genomic regions.

Details

Title
Dynamics of replication origin over-activation
Author
Fu Haiqing 1 ; Redon, Christophe E 1 ; Thakur, Bhushan L 1 ; Utani Koichi 2 ; Sebastian, Robin 1   VIAFID ORCID Logo  ; Sang-Min, Jang 3 ; Gross, Jacob M 1 ; Mosavarpour Sara 1 ; Marks, Anna B 1 ; Zhuang, Sophie Z 1 ; Lazar, Sarah B 1 ; Rao Mishal 1 ; Mencer, Shira T 1 ; Baris, Adrian M 4 ; Pongor Lorinc S 1   VIAFID ORCID Logo  ; Aladjem, Mirit I 1   VIAFID ORCID Logo 

 Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, USA (GRID:grid.417768.b) (ISNI:0000 0004 0483 9129) 
 Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, USA (GRID:grid.417768.b) (ISNI:0000 0004 0483 9129); Kanazawa Medical University, Department of Microbiology, Kanazawa, Japan (GRID:grid.411998.c) (ISNI:0000 0001 0265 5359) 
 Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, USA (GRID:grid.417768.b) (ISNI:0000 0004 0483 9129); Chungbuk National University, Department of Biochemistry, Cheongju, Korea (GRID:grid.254229.a) (ISNI:0000 0000 9611 0917) 
 Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, USA (GRID:grid.417768.b) (ISNI:0000 0004 0483 9129); Oregon Health and Science University, Program in Cancer Biology, Portland, USA (GRID:grid.5288.7) (ISNI:0000 0000 9758 5690) 
Publication year
2021
Publication date
2021
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2538876509
Copyright
© This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.